Closed-loop outpatient trial
Participants are still needed for the largest at-home trial of a hybrid closed-loop insulin pump system, led by Children’s Diabetes Centre researchers.
The national Hybrid Closed-Loop Outpatient Trial will test the use of an automated insulin delivery system to see if it is better at optimising blood glucose levels than standard therapy.
It will include 160 participants aged 12 to 25 and 120 adults aged 26 to 65 years.
The young people’s team is being led by Princess Margaret Hospital’s Professor Tim Jones, co-director of the Children’s Diabetes Centre, while Associate Professor David O’Neal, from Melbourne’s St Vincent’s Hospital, heads up the adult trial.
Professor Jones said researchers wanted to understand how hybrid closed-loop systems affected the quality of life of Type 1 diabetics, in addition to its potential savings to the healthcare system.
“The hybrid closed-loop system consists of an insulin pump, sensor with transmitter attached and a maths program (an algorithm) within the pump that automatically works out how much insulin is needed and is adjusted every five minutes,” Professor Jones said.
“This study will tell us if using an artificial pancreas is better than either insulin injections or normal insulin pump therapy at keeping blood glucose levels within the normal range.
“Researchers will also explore how this technology affects how people feel about managing diabetes, specifically through improving their blood glucose levels, reducing diabetes complications and making treatment easier — which all goes towards reducing the burden of diabetes.”
The Hybrid Closed-Loop Outpatient Trial is a multi-centre study involving a number of Australian hospitals, and is funded by the Type 1 Diabetes Clinical Research Network, an innovative clinical research program led by JDRF Australia and funded by a Special Research Initiative through the Australian Research Council.
For more information, email email@example.com